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RegulationEbola virus (EBOV) causes severe hemorrhagic fevers in humans and non-human primates. While the role of
the EBOV major matrix protein VP40 in morphogenesis is well understood, nothing is known about its
contributions to the regulation of viral genome replication and/or transcription. Similarly, while it was
reported that the minor matrix protein VP24 impairs viral genome replication, it remains unclear whether it
also regulates transcription, since all common experimental systems measure the combined products of
replication and transcription. We have developed systems that allow the independent monitoring of viral
transcription and replication, based on qRT-PCR and a replication-deﬁcient minigenome. Using these
systems we show that VP24 regulates not only viral genome replication, but also transcription. Further, we
show for the ﬁrst time that VP40 is also involved in regulating these processes. These functions are conserved
among EBOV species and, in the case of VP40, independent of its budding or RNA-binding functions.ker).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Ebola virus (EBOV) is a member of the family Filoviridae in the
orderMononegavirales (Sanchez et al., 2007). It is the causative agent
of severe hemorrhagic fevers in human and non-human primates
with high case fatality rates. Currently, there is neither a speciﬁc
therapy nor a licensed vaccine available, and EBOV is classiﬁed as a
biosafety level (BSL) 4 agent (Gene et al., 2009). Virus particles show a
characteristic thread-like appearance and consist of a central
ribonucleoprotein (RNP) complex containing the viral RNA (vRNA)
genome complexedwith the nucleoprotein NP, the viral polymerase L,
the polymerase cofactor VP35 and the transcriptional activator VP30.
The RNP is surrounded by a matrix space, containing the matrix
proteins VP40 and VP24, and a host cell-derived membrane, in which
the surface glycoprotein GP is embedded (Sanchez et al., 2007).
It is known that the RNP components alone are sufﬁcient for viral
genome replication and transcription, and these processes have been
intensively studied using minigenome assays. Minigenomes are
miniature versions of the viral genome, in which all viral open
reading frames are deleted, which makes their study feasible under
reduced biosafety conditions. Classical minigenomes consist of areporter gene (e.g. Renilla luciferase) ﬂanked by the non-coding
leader and trailer regions, which contain the minimal signals
necessary for replication and transcription (Muhlberger et al., 1998,
1999) (Fig. 1A). This cassette is usually cloned under the control of a
T7 promoter to allow generation of a vRNA-minigenome following
transcription by a T7 RNA-polymerase, although RNA Polymerase I
has also been successfully used for this purpose in ﬁloviral
minigenome systems (Groseth et al., 2005). The resulting vRNA-
minigenome is recognized by the RNP complex components NP, VP35
and L and replicated using a complementary cRNA-minigenome as an
intermediate. If the transcriptional activator VP30, which has been
implicated in overcoming a secondary RNA structure inhibiting viral
transcription but not replication (Weik et al., 2002), is also present,
the vRNA-minigenomes can be further transcribed intomRNAs, which
then lead to reporter activity. It is important to note that the number
of vRNA-minigenome templates available for use in transcription is
dependent on viral genome replication (Fig. 1A). An increase in viral
genome replication leads to an increase in templates available for
transcription and, thus, can lead to an increase in both mRNA levels
and reporter activity. Therefore, in minigenome systems reporter
activity as well as the amount of mRNA reﬂects not only viral
transcription, but also viral genome replication.
In addition to deﬁning the viral components necessary for
replication and transcription, minigenomes have also been used to
investigate the details of these processes, e.g. the role of the
Fig. 1. Replication-competent and replication-deﬁcient minigenomes. A) Replication-competent minigenome system. Aminigenome consisting of a reporter open reading frame and
the viral leader (ldr) and trailer (trl) regions is cloned into an expression plasmid ﬂanked by a promoter for the T7 RNA polymerase (T7p) and a Hepatitis delta virus ribozyme
(HDVRib). Upon coexpression with T7 RNA polymerase (T7-Pol) viral RNA minigenomes (vRNA) are synthesized, which can serve as templates for viral genome replication using
complementary anti-minigenomes (cRNA) as an intermediate, as well as for viral transcription to produce reporter mRNAs. B) Alignment of the termini of the leader region of the
genome and the trailer region of the antigenome. The 128 terminal bases of the leader, containing the replication promoter, and the 176 terminal bases of the trailer are shown. The
known promoter elements 1 and 2 (PE1 and PE2) in the leader are indicated. The UN5 repeats of the genomic PE2 and UN5 repeats that could serve as an antigenomic PE2 are
underlined and the U residues indicated. The transcription start signal is written in bold face, and the 55 bases that are deleted in the replication-deﬁcient minigenome are italicized.
Stars indicate conserved bases. C) Replication-deﬁcient minigenome system. Fifty-ﬁve bases in the trailer region of a replication-competent minigenome were deleted (indicated in
panel B) in order to destroy the antigenomic replication promoter. The genomic replication promoter and viral transcription promoter remained unchanged. The resulting vRNA-
minigenomes could serve as template for cRNA-production and transcription of mRNA; however, no vRNA could be synthesized from the cRNA intermediates, rendering
transcription efﬁciency in this assay independent of replication.
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2008; Modrof et al., 2002; Weik et al., 2002), the genomic regions
serving as replication promoters (Enterlein et al., 2009; Weik et al.,
2005), and differences in the transcription/replication capacities of
RNPs from different EBOV species (Groseth et al., 2005). In addition,
minigenomes have been used as screening tools for antiviral
approaches (Groseth et al., 2007), as well as forming the basis for
more complex infectious virus-like particle systems that allow the
study of virtually all steps of the viral life cycle without the need for
BSL-4 facilities (Hoenen et al., 2006; Watanabe et al., 2004;
Wenigenrath et al., 2010).
A role for matrix proteins in the regulation of viral genome
replication and transcription has been shown for a number of negative
strand RNA viruses, including Vesicular Stomatitis Virus, where a
regulatory role of M was ﬁrst shown more than 30 years ago (Clinton
et al., 1978), Inﬂuenza virus (Watanabe et al., 1996), Tacaribe virus
(Lopez et al., 2001), Rabies virus (Finke et al., 2003), Lassa virus (Hass
et al., 2004), and most recently Measles virus (Iwasaki et al., 2009).
Interestingly, it has also been shown that VP40, the major matrix
protein of EBOV, binds to RNA in a sequence speciﬁc manner (Gomis-
Ruth et al., 2003), although the nature of the bound RNA remains
unknown. Recently, a similar phenomenon was described for the
matrix protein of Borna disease virus, and it was suggested that thismight contribute to RNP condensation and, thus, regulation of
transcription and replication (Neumann et al., 2009). Nevertheless,
except for one study showing that the EBOV minor matrix protein
VP24 impacts on viral genome replication, and possibly transcription
(Watanabe et al., 2007), no studies have been performed investigating
a regulatory role for the ﬁloviral matrix proteins in viral genome
replication and transcription. Therefore, this study aimed to investi-
gate the effect of the EBOV matrix proteins on viral genome
replication and transcription using a replication-deﬁcient minige-
nome, which allows the independent study of these processes in
ﬁloviruses for the ﬁrst time.
Results
Establishment of assays to independently measure replication and
transcription
In order to study viral transcription independently of viral genome
replication, a replication-deﬁcient minigenome was designed in
which the antigenomic replication promoter was deleted. Until now
the only information available about the antigenomic promoter is that
the last 176 nucleotides of the trailer are sufﬁcient to allow replication
of DI particles and, thus, should contain the antigenomic promoter
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described in quite some detail (Weik et al., 2005). Therefore, in order
to identify putative antigenomic promoter elements, an alignment
between the leader region and the complementary trailer region was
performed (Fig. 1B). A high degree of homology was observed for the
promoter element 1 (PE1), which in the genomic promoter
encompasses the ﬁrst 55 bases of the leader. In addition, several
UN5 repeats in the trailer region, which could make up a putative
promoter element 2 (PE2), were also identiﬁed. The longest stretch
consisted of ﬁve UN5 elements starting at base 122, while three
shorter stretches containing two or three repeats started at bases 78,
131 or 161, respectively. However, based on the alignment it was
impossible to tell which of these elements might make up the
functional PE2. Therefore, a minigenome was constructed in which
the 55 bases most likely to contain the PE1 were deleted. This
minigenome was expected to allow transcription as well as
replication of cRNA-minigenomes, since the leader region harboring
the elements responsible for these functions was left undisturbed and
does not interact with the trailer region (Weik et al., 2005), but should
not allow replication of vRNA-minigenomes from the cRNA-mini-
genome templates (Fig. 1C). Therefore, the number of vRNA-
minigenome templates available for use in transcription should be
independent of viral genome replication, and reporter activityFig. 2. Establishment of assays to independently measure replication and transcription. A) q
with expression plasmids for a replication-competent minigenome (mg), the T7-RNA polym
EBOV RNP components NP, L, VP35 and VP30, as indicated, with VP35 and NP being presen
Subsequently, qRT-PCR targeting the Renilla luciferase gene was performed using strand-spe
minigenome assay followed by qRT-PCR was performed as described in panel A, with the
replication-competent minigenome. C) Reporter activity in a replication-competent minigen
assay components as indicated. At 48 h p.t. reporter activity, reﬂecting viral-genome replic
minigenome assay. HEK-293 cells were transfected with all replication-deﬁcient minige
transcription but not replication, was measured.obtained from such a minigenome should only be dependent on the
efﬁciency of viral transcription.
Further, in order to easily quantify the number of negative sense (i.e.
vRNA−) minigenome copies, which allows a direct measurement of
replication, as well as positive sense (i.e. cRNA−) minigenomes and
minigenome-derived mRNAs, strand speciﬁc two-step quantitative
real-time RT-PCRs (qRT-PCRs) targeting the luciferase reporter gene
were established. To assess this method, a classical minigenome assay
was performed and at 48 h post transfection (p.t.) total RNA was
extracted from the cells and subjected to analysis using this qRT-PCR
approach. Only minimal backgroundwas observedwhenminigenome-
encoding plasmid, but no plasmid encoding the T7RNApolymerasewas
transfected (Fig. 2A). Upon transfection of plasmids encoding all
components except the viral polymerase L, some vRNA (0.30±
0.16×106 copies) but no cRNA/mRNA was detected, consistent with
initial production of vRNA by the T7 polymerase. When all components
except the transcription factor VP30were present, a signiﬁcant increase
in the amount of vRNAwasdetectable (2.03±0.15×106 copies), aswell
as in the amount of cRNA/mRNA (1.08±0.34×106 copies), consistent
with vRNA replication via a cRNA intermediate. When all components
were present, the amount of cRNA/mRNAwas increased 8-fold (8.04±
0.21×106 copies), consistent with an increase in minigenome-encoded
reporter mRNA production in the presence of the transcription factorRT-PCR after replication-competent minigenome assay. HEK-293 cells were transfected
erase (T7) for initial transcription of the RNA-minigenome from plasmid DNA and the
t in all samples. At 48 h p.t. total RNA was extracted and subjected to DNase treatment.
ciﬁc primers for the RT step. B) qRT-PCR after replication-deﬁcient minigenome assay. A
only difference being that a replication-deﬁcient minigenome was used instead of a
ome assay. HEK-293 cells were transfected with all replication-competent minigenome
ation and transcription, was measured. D) Reporter activity in a replication-deﬁcient
nome assay components as indicated. At 48 h p.t. reporter activity, reﬂecting viral
Fig. 3. Inhibition of viral genome replication and/or transcription by VP24. A) Impact of
VP24 from different species on viral transcription and/or replication. HEK-293 cells
were transfected with all replication-competent minigenome assay components and
different amounts of pCAGGS-VP24 from different Ebola virus species, as indicated. At
48 h p.t. reporter activity, reﬂecting viral genome replication and transcription, was
measured. B) Inﬂuence of VP24 on expression of ZEBOV NP in a replication-competent
minigenome assay. Experiments were performed as in panel A. Forty-eight hours p.t.
cells were lysed and subjected to SDS-PAGE and Western blotting using a monoclonal
antibody directed against NP. Numbers above the blot are relative expression levels.
C) Inﬂuence of VP24 on viral genome replication. HEK-293 cells were transfected with
all replication-competent minigenome assay components and with or without 200 ng
pCAGGS-VP24, as indicated. At 48 h p.t. total RNA was extracted, DNase digested and
subjected to strand speciﬁc qRT-PCR. Data shown in this panel were obtained in the
same set of experiments as shown in Fig. 2A. D) Inﬂuence of VP24 on viral transcription.
HEK-293 cells were transfected with all replication-deﬁcient minigenome assay
components and with or without 200 ng pCAGGS-VP24, as indicated. At 48 h p.t.
reporter activity was measured.
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decrease by about 25% (1.52±0.25×106 copies). In contrast, when
using the replication-deﬁcient minigenome, no increase in the amount
of vRNA above background-levels (i.e. vRNA-levels in the absence of the
viral polymerase) was observed in the presence of L (Fig. 2B),
conﬁrming that no replication took place.
As expected, while measuring reporter activity in the classical
minigenome assay the highest levels were observed when all
components were present (2.8×107 RLU), whereas reporter activity
was greatly reduced when no VP30 was present (0.2×107 RLU), and
only background levels of reporter activity could be observed in the
absence of L (Fig. 2C). Thisﬁnding reﬂects the pattern of RNAexpression
observed in the qRT-PCR assays (c.f. Fig. 2A). In comparison to the
classical minigenome assay, the replication-deﬁcient minigenome
system showed a 100 fold reduction in reporter activity due to fact
that the T7-transcribedminigenome template is not ampliﬁed (Fig. 1C).
Nevertheless, reporter activity was readily detectable in the presence of
all RNP components (2.0×105 RLU) (Fig. 2D) and still 50 fold higher
than the background level (0.04×105 RLU). It has been previously
shown that reporter activity in minigenome systems is derived from
mRNA transcripts (Muhlberger et al., 1999). Therefore, this result
indicated that indeed the established system can detect viral transcrip-
tion in the absence of viral genome replication.
In summary, in a classical replication-competent minigenome
system replication can be assessed by quantifying the negative sense
vRNA-minigenomes using qRT-PCR. However, reporter activity in
such a system does not allow differentiation between replication and
transcription, since it is dependent on both these processes. In
contrast, reporter activity in a replication-deﬁcient minigenome is
independent of replication and, therefore, only reﬂects viral tran-
scription. The combination of vRNA quantiﬁcation with a replication-
competent minigenome and reporter activity measurement with a
replication-deﬁcient minigenome, therefore, allows differentiation
between replication and transcription.
VP24 inhibits both viral genome replication and transcription
It has been shown that in classical minigenome assays expression of
Zaire ebolavirus (ZEBOV) VP24 reduces reporter activity aswell as vRNA
and mRNA levels, as detected by Northern blotting (Watanabe et al.,
2007). The reduced vRNA levels clearly showed that viral genome
replication was impaired. However, from these results it could not be
excluded that the drop in reporter activity, as well as mRNA levels, was
an indirect effect of impaired replication and, therefore, a decreased
amount of vRNA templates available for transcription. Therefore, the
effect of VP24 on viral genome replication and transcription was
investigated using the newly established systems.
To ﬁrst conﬁrm the results of the study byWatanabe et al., classical
minigenome assays were performed in the presence of increasing
amounts of VP24 from three different EBOV species: Zaire ebolavirus
(ZEBOV), Sudan ebolavirus (SEBOV) and Reston ebolavirus (REBOV). As
previously reported, we observed a strong, dose dependent reduction
in reporter activity (Fig. 3A). This effect was somewhat stronger for
REBOV VP24 than for SEBOV or ZEBOV VP24; however, it cannot be
excluded that this was due to slight differences in the expression
levels of the respective proteins. The expression level of NP, which
was used as a representative for the viral support proteins necessary
for viral genome replication and transcription, was not signiﬁcantly
inﬂuenced by expression of VP24 (Fig. 3B).
To better characterize this observed reduction in reporter activity,
the RNA amounts in a classical minigenome assay in the presence of
VP24 were determined using the qRT-PCR assay. In addition,
replication-deﬁcient minigenome assays were also performed. It
was observed that in classical minigenome assays the vRNA amounts
in the presence of VP24 dropped to background levels of initial vRNA-
production by the T7 polymerase (Fig. 3C). This conﬁrmed that VP24
Fig. 4. Inhibition of viral genome replication and/or transcription by VP40. A) Reporter
activity in a replication-competent minigenome assay. HEK-293 cells were transfected
with all minigenome assay components and different amounts of VP40. As a control for
the expression of transfected genes a pGL2 plasmid expressing Fireﬂy luciferase was
cotransfected. Both Fireﬂy activity (expression of plasmid-encoded genes) and Renilla
luciferase activity (minigenome-derived gene expression) were measured after 48 h.
B) Inﬂuence of VP40 on expression of NP in a replication-competent minigenome assay.
Experiments were performed as in panel A. Forty-eight hours p.t. cells were lysed and
subjected to SDS-PAGE and Western blotting using a monoclonal antibody directed
against NP. Numbers above the blot are relative expression levels. C) Cytotoxicity of
VP40. HEK-293 cells were transfected with all minigenome assay components and
different amounts of VP40. Cell death was measured after 48 h using the CytotoxGlo
assay (Promega). Cell survival is given relative to cell survival in control cells
transfected without VP40. D) Inﬂuence of reduced plasmid-derived gene expression on
minigenome replication and/or transcription. Minigenome assays were performed as
in panel A in the presence of varying amounts of VP40 or varying amounts of either
Actinomycin D (ActD) or α-Amanitin (α-Ama). Fireﬂy activity was used to measure
plasmid-derived gene expression. Shown is the average minigenome-encoded Renilla
activity at 50% plasmid-derived gene expression. Error bars indicate standard deviation.
60 T. Hoenen et al. / Virology 403 (2010) 56–66does indeed have a negative impact on viral genome replication. Also,
cRNA/mRNA levels were dramatically reduced, almost to background
levels, in the presence of VP24. Similarly, reporter activity in a
replication-deﬁcient minigenome assay was completely abolished in
the presence of VP24 (Fig. 3D), demonstrating that VP24 has also a
direct effect on viral transcription, independent of its inﬂuence on
replication.
VP40 directly decreases minigenome-encoded reporter activity
In contrast to VP24, a role for VP40 in regulating viral transcription
and/or replication has so far not been studied. To address this issue,
classical minigenome assays were performed in the presence of
increasing amounts of VP40. To control for a possible impact of VP40
on plasmid-encoded protein expression, which is used for the
expression of the viral proteins required for minigenome replication
and transcription, a control plasmid encoding Fireﬂy luciferase under
the control of a Polymerase II-dependent promoterwas cotransfected. A
VP40-mediated dose-dependent decrease in both control Fireﬂy and
minigenome encoded Renilla activity was observed (Fig. 4A); at 400 ng
transfected pCAGGS-VP40, Fireﬂy activity dropped to 34% of the initial
activity, whereas Renilla activity was decreased to 16%. This drop in
Fireﬂy activity reﬂected the decrease in the expression level of NP,
which was used as a representative for the expression of viral support
proteins (Fig. 4B). In order to exclude that the observedeffectwasdue to
a general cytotoxic effect of VP40, a commercial cell viability assay was
performed after transfecting the components needed for a classical
minigenome assay, as well as increasing amounts of VP40. Relative cell
survival was not affected by transfection of VP40 even at very high
amounts (Fig. 4C), demonstrating that the observeddecrease in reporter
activity is not due to increased cell death resulting from transfection of
VP40. These data then suggest that VP40 indeed has a negative impact
on the expression of plasmid-encoded proteins.
As a result of this inhibition of expression of plasmid-encoded
proteins by VP40 it was unclear whether the observed drop in
minigenome-encoded Renilla luciferase activity in the presence of
VP40was due to a direct impairment ofminigenome replication and/or
transcription by VP40, or whether this was an indirect effect due to
reduced expression of the viral support proteins necessary to drive viral
genome replication and transcription. In order to eliminate this
possibility, a control experiment was performed in which expression
of plasmid-encoded genes was down-regulated by inhibition of RNA
Polymerase II, using either ActinomycinD (Hurley, 2002) orα-Amanitin
(Nguyen et al., 1996), and the resulting effect on minigenome
replication and transcription was determined. To this end, the activities
of both Fireﬂy luciferase, reﬂecting expression of plasmid-encoded
proteins, and Renilla luciferase, reﬂecting viral genome replication and
transcription, were measured. Increasing levels of inhibitors caused a
decrease in both expression of plasmid encoded proteins aswell as viral
genome replication and transcription (Suppl. Fig. 1).However, at similar
levels of inhibition of plasmid-encoded protein expression the inhibi-
tion of minigenome replication and transcription by Actinomycin D or
α-Amanitin was much less extensive than that caused by VP40. For
example, at inhibitor concentrations sufﬁcient to reduce Fireﬂy activity
(plasmid-encoded protein expression) to 50%, Renilla activity (viral
minigenome replication and transcription) was still at 78% (using
Actinomycin D) or 85% (usingα-Amanitin); whereas in the presence of
VP40 amounts sufﬁcient to reduce Fireﬂy activity to 50%, Renilla activity
was at 25% (Fig. 4D). This difference demonstrates that, in addition to an
impact on the expression of plasmid-encoded proteins, VP40 also has a
direct impact on viral genome replication and/or transcription.
VP40 blocks both viral genome replication and transcription
In order to better understand how expression of VP40 regulates
viral genome replication and/or transcription, classical minigenome
Fig. 5. Characterization of VP40-mediated regulation of viral genome replication and/or
transcription. A) Inﬂuence of VP40 on viral genome replication. HEK-293 cells were
transfected with all replication-competent minigenome assay components and with or
without 400 ng pCAGGS-VP40, as indicated. At 48 h p.t. total RNA was extracted, DNase
digested and subjected to strand speciﬁc qRT-PCR. B) Inﬂuence of VP40 on viral
transcription. HEK-293 cells were transfected with all replication-deﬁcient minige-
nome assay components and with or without 400 ng pCAGGS-VP40, as indicated. At
48 h p.t. reporter activity was measured. C) Species and genus speciﬁcity of VP40
regulation of viral genome replication and transcription. HEK-293 cells were
transfected with all replication-competent minigenome assay components and
400 ng of pCAGGS-VP40 from different ﬁlovirus species and genera, as indicated. At
48 h p.t. reporter activity, reﬂecting replication and transcription, wasmeasured. Values
were normalized to the maximum expected levels of Renilla activity, taking into
consideration the inﬂuence of VP40 on cellular gene expression.
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different RNA species quantiﬁed. In the presence of VP40 vRNA levels
were reduced (p=0.03), compared to vRNA levels in the absence of
VP40, suggesting that viral genome replication is impaired by VP40,
and reached absolute levels comparable to background levels in the
absence of L (Fig. 5A). The levels of cRNA/mRNA showed a 7-fold
decrease in the presence of VP40, compared to levels obtained in the
absence of VP40, but did not reach background levels. This is
consistent with the observation that reporter activity is reduced to
about 16%, but not completely abolished (c.f. Fig. 4A, 400 ng pCAGGS-
VP40 transfected), and demonstrates that viral support proteins are
still expressed in the presence of VP40.
To further assess the impact of VP40 on viral transcription,
replication-deﬁcient minigenome assays were then performed
(Fig. 5B). Here a very strong reduction (96%) in reporter activity was
observed in the presence of VP40when compared to reporter activity in
the absence of VP40, indicating a strong negative regulation of viral
transcription by VP40. Thus, VP40 seems to inﬂuence both viral
transcription and viral genome replication.
The function of VP40 is conserved among species and genera
The amino acid sequences of VP40 from different EBOV species are
very highly conserved; however, there is a signiﬁcant amount of
divergence between EBOV VP40 and VP40 from the closely related
Marburg virus (MARV). Therefore, it was of interest whether VP40
from these different species and genera are still able to fulﬁl the
function of ZEBOV VP40 in regulating viral transcription and
replication. To address this question, classical minigenome assays
were performed in the presence of ZEBOV, REBOV, SEBOV or MARV
VP40. In all cases a reduction in reporter activity to levels between 5%
and 17%, compared to activity in the absence of VP40, was observed
with no signiﬁcant differences between the VP40 from the different
species and genera (data not shown). However, as with our earlier
experiments with ZEBOV (Fig. 4A and D) this reduction was only
partially due to a direct effect of VP40 on replication and transcription,
but also partially due to the inhibitory effect of VP40 on the expression
of genes from cellular promoters, which impairs expression of the
minigenome assay components. To address this, Fireﬂy levels
reﬂecting this inhibitory effect were measured in each sample, and
Renilla reporter activity was normalized to the Renilla activity
observed at equivalent Fireﬂy levels after Actinomycin D treatment;
thereby eliminating the indirect inﬂuence of VP40 on viral genome
replication and viral transcription due to inhibition of cellular
promoters. A signiﬁcant reduction in reporter activity was observed,
with no signiﬁcant differences between VP40 from the different
species and genera (Fig. 5C).
The function of VP40 is independent of its budding function and RNA
binding ability
VP40 has previously been shown to induce the formation of virus-
like particles, and to recruit RNP components, including encapsidated
minigenomes, into these particles (Hoenen et al., 2006; Johnson et al.,
2006; Noda et al., 2006; Watanabe et al., 2004). Therefore, we wanted
to address whether this budding activity of VP40 is linked to its
regulatory effect on viral genome replication and transcription. To this
end the two late-domain motifs in VP40, which are known to be
essential for its budding activity, were destroyed through the
introduction of point mutations (P10A, P11A). The resulting VP40-
P10/11A has been previously shown to be completely inactive in terms
of virus-like particle production, but to be expressed equally well
compared to VP40-WT (Neumann et al., 2005).When this mutant was
tested in a classical minigenome assay, we observed a reduction in
normalized reporter activity to exactly the same levels (13.5±5.5%
reporter activity) as VP40-WT (15.7±5.4% reporter activity) (Fig. 6A),indicating that budding of VP40 does not inﬂuence its impact on viral
genome replication and transcription.
It has also been previously shown that VP40 of ZEBOV binds RNA in
a sequence-speciﬁc manner (Gomis-Ruth et al., 2003), although the
identity of the bound RNA is unknown. An RNA binding-deﬁcient
mutant of VP40 (VP40-R134A) has been identiﬁed (Hoenen et al.,
2005), and was used to investigate the relevance of RNA binding for
Fig. 6. Inﬂuence of RNA-binding and budding activity of VP40 on regulation of viral
genome replication and transcription. A) Effect of budding-incompetent or RNA
binding-deﬁcient VP40 in a replication-competent minigenome assay. HEK-293 cells
were transfected with all replication-competent minigenome assay components and
400 ng of an expression vector encoding wild-type VP40 (VP40-WT) or amutated VP40
that was either no longer able to speciﬁcally bind RNA (VP40-R134A) or undergo
budding (VP40-P10/11A), as indicated. At 48 h p.t. reporter activity reﬂecting replication
and transcription was measured. B) Inﬂuence of VP40-R134A on viral genome
replication. HEK-293 cells were transfected with all replication-competent minige-
nome assay components and with or without 400 ng pCAGGS-VP40-R134A, as indicated.
At 48 h p.t. total RNA was extracted, DNase digested and subjected to strand speciﬁc
qRT-PCR. C) Inﬂuence of VP40-R134A on viral transcription. HEK-293 cells were
transfected with all replication-deﬁcient minigenome assay components and with or
without 400 ng pCAGGS-VP40-R134A, as indicated. At 48 h p.t. reporter activity was
measured.
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this end classical minigenome assays were performed in the presence
of either wild type ZEBOV VP40 or ZEBOV VP40-R134A, which are also
equally well expressed after transfection (Hoenen et al., 2005). As
previously observed, a strong decline in reporter activity (84.3±5.4%)was detected in the presence of VP40-WT (Fig. 6A). While in the
presence of VP40-R134A this decline was somewhat smaller (65.3±
16.1%), this difference was not statistically signiﬁcant. To further
conﬁrm that there is no difference between VP40-WT and VP40-R134A
in terms of their ability to regulate viral genome replication and
transcription, these two processes were individually analyzed. vRNA
levels in a classical minigenome assay were virtually identical when
comparing the inﬂuence of VP40-WT and VP40-R134A on replication
(Fig. 6B). Further, there was no signiﬁcant difference in reporter
activity between VP40-WT and VP40-R134A in a replication-deﬁcient
minigenome assay (Fig. 6C). These results further conﬁrm that RNA-
binding by VP40 does not play a role in the regulation of viral genome
replication and transcription.
Discussion
Minigenome systems have been extremely useful in studying the
life cycle of Mononegavirales (Ebihara et al., 2005; Hoenen et al.,
2007). In these systems a vRNA-minigenome is ampliﬁed by viral
genome replication and then serves as a template for viral
transcription, leading to the production of mRNAs and, eventually,
reporter activity (Fig. 1A). The mRNA amount, as well as reporter
activity, is inﬂuenced by both viral genome replication and transcrip-
tion and, therefore, it has been problematic to differentiate between
these two processes. While for minigenome systems replication could
be assessed directly using Northern blot techniques (Muhlberger et
al., 1999; Watanabe et al., 2007), in the past viral transcription has
been directly assessed only by use of in vitro transcription assays
(Banerjee et al., 1991; Neumann et al., 2004). Unfortunately, such
systems are not available for ﬁloviruses. We have, therefore,
developed an approach that allows easy quantiﬁcation of replication
and transcription independently of each other. This approach is based
on a combination of strand speciﬁc quantitative RT-PCR to detect
changes in replication, and a replication-deﬁcient minigenome to
allow speciﬁc monitoring of transcription.
While establishing the replication assayweobserved that even in the
absence of the viral polymerase a signiﬁcant amount of vRNA was
produced, presumably by transcription of the minigenome by the T7
RNA polymerase. However, it is unclear to what extent these vRNAs
were encapsidated and, therefore, able to serve as functional templates
for viral genome replication and transcription. Indeed, it has been
suggested that “illegitimate” encapsidation of already transcribed, but
naked vRNAs of non-segmented negative-strand RNA viruses (NNSVs)
is a very inefﬁcient process (Conzelmann, 2004), a concept thathas been
experimentally demonstrated for Respiratory Syncytial Virus (RSV) and
Vesicular Stomatitis Virus minigenomes (Pattnaik et al., 1992; Peeples
andCollins, 2000).Uponexpressionof all RNPcomponents exceptVP30,
vRNA replication, as well as synthesis of positive stranded RNA species
(cRNA and/or mRNA), was observed. However, only very little reporter
activity could be measured, suggesting that the majority of positive
strand RNAwas cRNA. Interestingly, the amount of vRNA producedwas
much larger than the amount of cRNA, a ﬁnding which has also been
reported for othermembers of theorderMononegavirales (Whelanet al.,
2004), and which is generally attributed to differing strengths of the
genomic and antigenomic promoter.
Upon coexpression of VP30 in this assay, a strong increase in the
amount of positive strand RNA was observed, together with a strong
increase in reporter activity. This is consistent with a previous report
showing that VP30, while not absolutely required for reporter activity,
leads to a signiﬁcant increase in reporter expression (Muhlberger et al.,
1999). Interestingly, theamount of vRNAshoweda small decrease in the
presence of VP30.Whether this is due to a regulatory action of VP30, i.e.
switching the polymerase from a replicase function to a transcriptase
function, is unclear, but it is interesting to note that such a role has been
shown for the P proteins of othermembers ofMononegavirales (Pattnaik
et al., 1997; Saikia et al., 2008). Thus itmay bepossible that the functions
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transcription have, in the case ofﬁloviruses, beendividedbetweenVP35
and VP30, respectively, as has been previously suggested (Muhlberger,
2007).
In order to develop a system that enables us to analyze viral
transcription, in the absence of secondary effects from alterations in
viral genome replication, we created a replication-deﬁcient mini-
genome, similar to replication-deﬁcient minigenomes that have been
developed for RSV (Peeples and Collins, 2000). In this construct the
putative PE1 element of the antigenomic promoter, as identiﬁed by an
alignment to the known regions of the genomic promoter, was
deleted. While in theory the complementarity of the EBOV leader and
trailer regions allows an interaction of the genome ends in the form of
a panhandle structure, it has been experimentally shown that they
rather form individual hairpin structures, and do not interact with
each other (Weik et al., 2005). Therefore, it was reasonable to assume
that the deletion in the trailer region would not inﬂuence the function
of the transcriptional promoter located in the leader. Also, for the RSV
minigenome system it has been shown that deletions in the trailer
region do not inﬂuence synthesis of mRNA and cRNA, despite the RSV
leader and trailer regions showing a high complementarity similar to
the ends of the EBOV genome (Peeples and Collins, 2000). Indeed, the
replication-deﬁcient minigenome performed as expected and showed
reporter activity only in the presence of all RNP components,
including VP30, while no replication could be observed. VP30 greatly
enhanced viral transcription in this system, further supporting its role
as a transcription factor (Muhlberger et al., 1999). Interestingly,
reporter activity derived from the replication-deﬁcient minigenome
was about 140-fold lower than in a classical minigenome assay,
demonstrating the importance of viral genome replication for the
overall reporter activity in minigenome assays. This observation can
be easily explained by the fact that only encapsidated vRNA can serve
as a template for the viral polymerase, and supports the hypothesis
that successful encapsidation occurs for only a very small fraction of
the T7-transcribed vRNA-minigenomes.
Matrix proteins have been known to regulate replication and/or
transcription for more than 30 years (Clinton et al., 1978). For
Rhabdoviruses it was reported that the matrix protein M inhibits viral
transcription of puriﬁed RNP complexes (Carroll and Wagner, 1979).
This effect has been suggested to be linked to the ability of M to
condense RNP complexes into tight structures that are no longer able to
serve as templates for transcriptionor replication (De et al., 1982). Itwas
also shown that even prior to condensation of RNP complexes M shifts
the balance between replication and transcription towards replication
(Finke et al., 2003), and that this function can be genetically separated
from other functions of M (Finke and Conzelmann, 2003). For
Paramyxoviruses it has been recently reported that M inhibits viral
genome replication and/or transcription by interacting with the
nucleoprotein N (Iwasaki et al., 2009). Similarly, the matrix protein Z
of Tacaribe virus inhibits replication and/or transcription in a
minigenome assay (Lopez et al., 2001), and this inhibition is dependent
on an interaction between Z and the viral polymerase L (Jacamo et al.,
2003). In the present studywe have shown that bothmatrix proteins of
EBOV, VP40 and VP24, are able to inhibit both viral genome replication
and transcription.
The presence of VP24 is necessary to support the formation of RNP-
like structures by NP and VP35, which are similar to the nucleocapsids
found in virus particles or within infected cells (Huang et al., 2002;
Watanabe et al., 2006). Interestingly, VP24 is not required for replication
or transcription of minigenomes, suggesting that the RNP-like struc-
tures are not required for these processes, but might rather constitute
condensed nucleocapsids ready for incorporation into particles. Also,
using an infectious virus-like particle assay we could demonstrate that
VP24 is required for the formation of fully functional nucleocapsids able
to undergo primary transcription in newly infected target cells (Hoenen
et al., 2006). In cells infected with the related MARV, VP24 has beenfound associated with free nucleocapsids within the cytoplasm, as well
as close to the plasma membrane, and was further shown to interact
with NP (Bamberg et al., 2005). We, therefore, propose that VP24 is
involved in the condensation of nucleocapsids, and that the observed
inhibition of replication and transcription in the presence of VP24 is due
to this process.
In contrast to this, VP40 is not able to induce the formation of RNP-
like structures togetherwith NP and VP35 (Huang et al., 2002), although
it has been shown to directly interact with NP (Noda et al., 2007).
Therefore, it can be assumed that VP40 inﬂuences replication and
transcription by a mechanism other than RNP condensation. Part of the
observed reduction of reporter activity can be explained by the inﬂuence
of VP40 on cellular gene expression and, therefore, also on the
expression of the minigenome assay components. A similar effect of
viralmatrix proteinson cellular gene expressionhas beendescribed for a
number of Rhabdoviruses, including Vesicular Stomatitis Virus, Infec-
tious hematopoietic necrosis virus and Chandipura Virus (Black and
Lyles, 1992; Chiou et al., 2000; Taylor et al., 1999). Also,we have recently
observed a similar effect for MARV VP40 (Wenigenrath et al., 2010). To
analyze the extent to which this effect on cellular gene expression is
responsible for the reduction in minigenome replication and/or
transcription, a control experiment was performed in which cellular
gene expression was down-regulated using either Actinomycin D or α-
Amanitin. α-Amanitin speciﬁcally inhibits RNA Polymerase II by
triggering degradation of its largest subunit (Nguyen et al., 1996),
while Actinomycin D inhibits cellular transcription by interacting with
the DNA-templates (Hurley, 2002). There are a number of mechanisms
of action that have been described for Actinomycin D, including binding
to CG-rich DNA (Scamrov and Beabealashvilli, 1983), binding to single-
stranded (YooandRill, 2001) or hairpin (Wadkins et al., 1998) structures
as well as binding of G-Quadruplexes (Kang and Park, 2009). It has been
shown that Actinomycin D can inhibit viral genome replication as well;
however, this is only the case for viruses which produce single-stranded
DNA-intermediates during replication (Jeeninga et al., 1998). Also,
ActinomycinDdoes not bindRNA (Bunte et al., 1980) anddoes not affect
replication of NNSVs.
When cellular gene expression was down-regulated using Actino-
mycinDorα-Amanitin,minigenome reporter activitywas impaired to a
lesser extent than when plasmid-encoded protein expression was
down-regulated to the same extent by VP40. Together with the data
from the qRT-PCR, as well as the replication-deﬁcient minigenome, this
suggests that VP40 has an additional, direct effect on both viral genome
replication and transcription, in addition to its effect on cellular gene
expression.
The inﬂuence of VP40 on viral transcription and replication was
independent of the budding ability of VP40, which may induce
changes in the intracellular concentrations of RNP complex compo-
nents by recruiting these components into virus-like particles. It was
at ﬁrst somewhat surprising that destroying the budding ability of
VP40 did not lead to an increased intracellular concentration of VP40
and, therefore, to a stronger impairment of replication and transcrip-
tion. However, the budding induced by VP40 alone is a relatively
inefﬁcient process and the amount of intracellular VP40 is much
higher than the amount of VP40 found in the supernatant (unpub-
lished data). Therefore, the intracellular amount of VP40 is not
signiﬁcantly increased when budding activity is impaired, which is
consistent with data published by others (Neumann et al., 2005).
Although the RNA-binding ability of VP40 is essential for the viral
life cycle (Hoenen et al., 2005), it does not seem to inﬂuence its ability
to impair replication and transcription. It has to be noted that the
identity of the RNA bound by VP40 is still unknown; however, the
RNA-binding activity of VP40 can be observed in absence of viral RNA
(Gomis-Ruth et al., 2003; Hoenen et al., 2005), and it is currently
unclear whether VP40 binds viral RNA or minigenomes at all.
Together with the fact that VP40 is not necessary for the formation
of nucleocapsid-like structures, this makes a participation of EBOV
64 T. Hoenen et al. / Virology 403 (2010) 56–66VP40, and particularly its RNA-binding ability in RNP condensation, as
has been proposed for Borna disease virus M (Neumann et al., 2009),
unlikely. Therefore, the exact mechanism by which VP40 affects viral
genome replication and transcription remains a subject for future
study; however, based on a recent publication concerning measles M
(Iwasaki et al., 2009), the interaction of VP40 with NP will be of
particular interest in these studies.
Until now there have been no systematic studies looking at the
expression proﬁles of ﬁlovirus proteins during one replication cycle.
However, it is important to note that the amounts of VP24 and VP40
used in the present study are similar to the amounts necessary for
these proteins to fulﬁl their biological functions in an iVLP assay,
which is the most authentic in vitro system currently available to
model the viral life cycle (Hoenen et al., 2006; Watanabe et al., 2004).
Based on the current model of transcription of NNSVs, it is generally
assumed that there is a transcriptional gradient favouring expression
of viral proteins closer to the 3′-end of the genome (Banerjee et al.,
1991). Interestingly, VP24, which appears to be a very potent inhibitor
of viral genome replication and transcription, is located close to the 5′-
end of the genome and is, therefore, most likely expressed at low
levels. This ﬁts nicely to a model in which viral genome replication
and transcription takes places, leading to increasing levels of VP24,
which only late in the replication cycle accumulate to levels sufﬁcient
to inhibit further genome replication and transcription, possibly by
inducing condensation of RNP complexes. Testing this model and
assessing the role of VP24 and VP40 during the course of a natural
infection will be important topics for future studies.
Materials and methods
Cells
HEK-293 (human embryonic kidney) cells were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM, Invitrogen) supplemen-
ted with 10% fetal bovine serum (FBS, PAN Biotech.), 2 mM L-glutamine
(Q, Invitrogen), 100 U/ml penicillin and 100 μg/ml streptomycin (P/S,
Invitrogen) unless otherwise indicated, and grown at 37 °C and 5% CO2.
Escherichia coli (E. coli) of the XL-1 Blue strain were used for all routine
cloning procedures.
Virus propagation and RNA isolation
SEBOV (strain Gulu) and REBOV (strain Pennsylvania) were
propagated in Vero E6 cells (ATCC CRL 1586) in the BSL-4 laboratory
at the Philipps UniversityMarburg as previously described (Muhlberger
et al., 1992). For both viruses supernatant was inactivated in a
guanidinium isothiocyanate-based buffer (AVL buffer, RNeasy kit,
Qiagen), and RNA was extracted according to the manufacturer's
directions.
Plasmids
All minigenome assay components, including ZEBOV expression
plasmids (pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, pCAGGS-L,
pCAGGS-VP40, pCAGGS-VP24, pCAGGS-GP) and the classical mini-
genome expression plasmid (3E5E-luc), have been previously de-
scribed (Hoenen et al., 2006). Expression plasmids for VP24 of SEBOV
and REBOV were constructed by cloning the relevant open readings
frames into the vector pCAGGS (Kobasa et al., 1997; Niwa et al., 1991)
via the restriction sites XmaI and NotI using a conventional RT-PCR
based approach. Similarly VP40 of SEBOV and REBOVwere cloned into
pCAGGS using the restriction sites KpnI and NheI or BamHI and XhoI,
respectively. The VP40 mutant VP40-R134A has been previously
described (Hoenen et al., 2005), and the mutant VP40-P10/11A was
constructed using standard site directed mutagenesis techniques.The replication-deﬁcient minigenome was cloned from a classical
minigenome by using PCR to amplify a linearized version of the plasmid
lacking 55 bases of the trailer. This linear DNA fragment was
phosphorylated using T4-polynucleotide kinase (New England Biolabs)
and religated using T4-DNA ligase (New England Biolabs).
The sequence of all plasmids was conﬁrmed prior to use.
Minigenome assay
Minigenome assays were performed as previously described
(Hoenen et al., 2006; Muhlberger et al., 1999). Brieﬂy, 60% conﬂuent
HEK-293 cells cultured in 6 well plates were transfected with the
following plasmids using 3 µl TransIT LT1 (Mirus) per µg of DNA and
according to the manufacturer's instructions: 125 ng pCAGGS-NP,
125 ng pCAGGS-VP35, 75 ng pCAGGS-VP30, 1000 ng pCAGGS-L,
250 ng 3E5E-minigenome, 250 ng pGL2-Control (Promega) and
250 ng pCAGGS-T7, unless otherwise indicated. Differences in the
absolute plasmid mass transfected were compensated for by the
addition of empty pCAGGS vector. Prior to transfection the medium
on the cells was changed to 2 ml DMEM supplemented with 5% FBS
and Q. Formation of transfection complexes was carried out in 100 µl
Optimem (Invitrogen). At 24 h post transfection (p.t.) the medium
was exchanged against 4 ml of DMEM supplemented with 5% FBS, Q
and P/S. After 48 h p.t. cells were scraped into 1 ml PBS, of which
900 µl were used for minigenome RNA extraction, while 25 µl 5×
passive lysis buffer (Promega) was added to the remaining 100 µl.
This lysate was frozen once at −20 °C, thawed, vortexed for 5 s and
cellular debris was pelleted by centrifugation for 3 min at 10,000×g.
Reporter activity in the supernatant was then determined using the
Dual luciferase reporter assay (Promega) and measured with a Centro
LB 960 luminometer (Berthold Technologies).
Minigenome RNA extraction and strand speciﬁc two step quantitative
real-time PCR
RNA-extraction was performed using the RNeasymini kit (Qiagen)
according to the manufacturer's instructions, and included the
optional on-column digestion with the RNase-Free DNase Set
(Qiagen). The RNA was eluted in 50 µl RNase-free water, and 10 µl
was used for reverse transcription using the Omniscript RT kit
(Qiagen) in the presence of 10 U RiboLock RNase inhibitor (Fermen-
tas) following the manufacturer's instructions. As the primer for
cDNA/mRNA detection the oligonucleotide luc(−) 5′-AGA ACC ATT
ACC AGA TTT GCC TGA-3′ was used, and as the primer for vRNA
detection the oligonucleotide luc(+) 5′-GGC CTC TTC TTA TTT ATG
GCG A-3′ was used. Subsequently, quantitative real-time PCR was
performed on a StepOne Real-Time PCR system (Applied Biosystems)
using the QuantiFast SYBR Green PCR kit (Qiagen) with 5 µl cDNA as a
template and both the luc(−) and luc(+) primers according to the
manufacturer's instructions. Minigenome plasmid DNA was used to
standardize the genome copy numbers.
Actinomycin D and α-Amanitin treatment
Cells were transfected with all minigenome components as
described above. At 6 h p.t. the medium was exchanged against 4 ml
of DMEM supplemented with 5% FBS, Q and P/S. Actinomycin D
(Sigma) was dissolved in DMSO, and a 1:2 dilution series was made.
Subsequently, 10 µl of Actinomycin D in DMSO or 10 µl of DMSO alone
was added to the cells for a ﬁnal Actinomycin D concentration of 0, 10,
20, 40, 80, 160 or 320 ng/ml. α-Amanitin was dissolved in water at a
concentration of 1 mg/ml, and was added to the cells at ﬁnal
concentrations of 0, 0.1, 0.33, 1, 3 and 10 μg/ml. Reporter activity in
the presence of inhibitors was measured at 48 h p.t. as described
above.
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To determine the effect of VP40 on cell viability in a minigenome
assay, plasmids encoding all minigenome components, as well as 0 to
800 ng pCAGGS-VP40, were transfected as described above; however,
transfection was performed in a 96 well optical bottom cell culture
plate (Nunc), with the mass of plasmids and amount of transfection
reagent used adjusted according to the surface area. At 48 h p.t. the
cell viability was determined using the CytoToxGlo assay (Promega)
following the manufacturer's instructions (Niles et al., 2007).
Statistical analysis
To check for statistically signiﬁcant differences Student's t-tests
were performed using the QuickCalcs online calculator (Graphpad
Software; http://www.graphpad.com/quickcalcs/ttest1.cfm).
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